FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
Related coverage: FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma Targeted Oncology
Aug 13, 2026
Publisher
Targeted Oncology News
The latest headlines and summaries aggregated from Targeted Oncology on AIMode News.
2 recent stories from Targeted Oncology
Advertisement
Advertisement
Health
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
Related coverage: FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma Targeted Oncology
Health
FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs
Related coverage: FDA Does Not Approve 177Lu-Edotreotide for GEP-NETs Targeted Oncology